Yusuf Hamied, often referred to as the grand old man of the Indian pharmaceutical industry, was in London to propagate his vision of Indian companies being free to manufacture and market drugs at an affordable cost.
"It is important to have a compulsory licensing system. In fact, I am in favour of obligatory licensing where we don't mind paying royalties to the patent holder but at least Indian companies should be able to manufacture and market essential drugs to make them more accessible in the Third World," he said.
Hamied, who stepped down as Cipla's managing director earlier this year to take on a mentor's role, said: "What is good enough for the Canadians, should be good enough for the Indians.
"There is big obsolescence in the drugs industry and new drugs are coming up all the time. But we Indians are impotent because we can't manufacture and market them.
"We don't want to encroach on the regulated developed world markets of the world. Just leave the developing world to us so that we don't deprive millions and ensure access to affordable drugs."
He set the global health community abuzz a decade ago when he said he could produce cocktails of AIDS medicines for a dollar per day, and that price has since fallen to 20 cents a day.
"The one thing that brings greatest satisfaction is that in 2001, only between 2,000 and 4,000 Africans could afford the anti-AIDs drugs. Today, nine million are being treated," he said.
"It is time India takes its correct position in healthcare because our policies will affect millions, not only in India but in the rest of the developing world.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
